CSF3 and small cell lung carcinoma: In fact, our search confirmed a substantially high rate of grade 3/4 neutropenia (51–91%) observed in SCLC patients treated with etoposide/platinum chemotherapy given the fact that G-CSF use has been allowed in 3 out of nine trials.